JERSEY CITY, N.J., Aug. 08, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended June 30, 2017, and provided an update on recent operational and clinical developments.
“During the quarter, we commenced enrollment in our Phase 2 trial for vulvovaginal candidiasis, an indication for which oral SCY-078 may address a large unmet therapeutic need.
